Big Data Marketing Pharma Companies Regulation 
pharmaphorum
JULY 14, 2022
A pilot study has been launched by the EMA to see whether it is helpful for regulators to look at the ‘raw data’ from clinical trials submitted in support of new marketing application along with the usual structured analyses from sponsors. It may also help the regulator to define target treatment populations better.
Drug Discovery World
FEBRUARY 6, 2024
Technologies like artificial intelligence (AI), machine learning (ML) and robotics/automation are enabling researchers to process enormous data sets and conduct preclinical investigations in record time, speeding up the process and offering greater accuracy. AI brings exciting opportunities to generate new insights and improve processes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 16, 2021
COVID-19 has disrupted markets and accelerated digital adoption but what does this mean for the future of marketing? In this feature, Grünenthal’s Florent Eduoard and Kate Hurtig outline their principles for a new pharmaceutical marketing model. . The R&D focus began to shift, and so did the marketing.
Pharma Marketing Network
JUNE 11, 2020
RJ Lewis (EHS): Hello, this is RJ Lewis and we’re back for Episode 2 with John Mack and Don Langsdorf, and we’re talking about the rebirth of Pharma Marketing and Pharma Guy. So, you continue with Pharma Marketing news. So they all do things that they do very well and they cover the market very well.
pharmaphorum
DECEMBER 22, 2021
The ‘PEP Talks’ monthly e-newsletter has approaching 50 pharma companies as subscribers and the inaugural ‘Patient Engagement Day’ on September 01 st achieved an inspirational number of downloads of toolkits for ways to ‘Amplify the Patient Voice’ as the launch theme. Will pharma listen, and is this even their role to do so?
Expert insights. Personalized for you.
52 
Let's personalize your content